LONDON and WILMINGTON, N.C. and MILAN, June 9, 2014 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), and the Society for Applied Pharmacological Sciences (SSFA) today, jointly announce the appointment of Dr.Marco Romano as President of SSFA for a three year appointment.
Sabrina Lucioni, Secretary of SSFA, stated: "Dr. Marco Romano's recent promotion to President is a well deserved acknowledgement of his professional experience and dedication to the life of our Italian Medical Association through his participation in several initiatives such as Courses, Congresses, Conferences, and as one of the authors of our bi-monthly Magazine SSFAOGGI."
Prior to joining Chiltern in 2007 where he serves as Chief Medical Officer, Dr. Romano received his medical degree in 1983 at the University of Genova, Italy, where he went on to post-graduate studies in hygiene, epidemiology, and public health, followed by another post-graduate degree in 1994 in clinical pharmacology at the University of Milan, Italy. He is co-author of several scientific papers on the topics of mutagenesis and cancerogenesis, pharmacokinetics and pharmacodynamics of chemical compounds and glutathione metabolism. He has been a member of the Italian Medical Association for 31 years and a member of the Italian Society for Applied Pharmaceutical Sciences for more than 15 years, where he has served as Treasurer and Vice President. Dr. Romano has been working in pharmaceutical and clinical research organizations for 25 years.
"We have had the great honor to work with Dr. Romano for the past several years and are excited about his new role as President of SSFA," offeredSharon Moore, Chiltern's Executive Vice President of Global Medical and Regulatory affairs. "We are confident that his dedication to research and development, and his ability to work among all stakeholders, will greatly benefit the SSFA and its members. Congratulations to Dr. Romano and to the SSFA on its 50th anniversary."
Aize Smink, Chiltern's Chief Operating Officer went on to add: "On behalf of Chiltern, it is a great pleasure to congratulate you, Marco, with your nomination as President of the Italian SSFA. It is clear that the SSFA has recognised your experience and leadership in Clinical Research gained over many years working in various roles. We can be proud to have such a driven, engaged person as part of our organisation, and we will benefit of being represented by you in Italy and internationally. I wish you all the best in this position and I am certain the Society will flourish under your leadership."
Company profiles
About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,700 people globally and offers services in Global Clinical Development, Global Scientific Services, and Global Resourcing Solutions. Chiltern prides itself as a development partner that offers innovation, responsiveness and quality delivery.
Further information is available at: www.chiltern.com.
About SSFA:
SSFA was founded in 1964 by mainly pharmacologists and toxicologists. This year the society celebrates 50 years where the significant growth in membership is recognized. The society supports patent Italian law on drugs and is one of the most represented scientific professions in the Italian pharmaceutical companies.
For more information contact:
Nicholas Spittal
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
2528 Independence Blvd. Suite 101
Wilmington, NC 28412
USA
Tel: +1 (910) 338 4760
Email: [email protected]
SOURCE Chiltern; SSFA